Skip to content

Exploring Blood Biomarkers for Better Diagnosis and Treatment of Bipolar Disorder with Mixed Features

Mechanistic Analysis and Treatment Response Prediction of Bipolar Disorder with Mixed Features Based on Multi-Dimensional Blood Biomarkers

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600119003
Enrollment
Unknown
Registered
2026-02-13
Start date
2026-03-01
Completion date
Unknown
Last updated
2026-02-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bipolar Disorder Depressive Episode

Interventions

BD-DNMX Group:N/A
BD-DMX Group:N/A
Healthy Control Group:N/A

Sponsors

Huzhou Third Municipal Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
15 Years to 55 Years

Inclusion criteria

Inclusion criteria: Patient Group (BD-DMX/BD-DNMX): 1. Meet the DSM-5 criteria for bipolar disorder depressive episodes; 2. BD-DMX Group: depressive episodes with >=3 manic symptoms (CUDOS-M-S score >=8); 3. BD-DNMX Group: depressive episodes with =17, age 15-55 years. Healthy Control Group: 1. Age and gender matched with the patient group; 2. No history of psychiatric disorders or family history of mental illness.

Exclusion criteria

Exclusion criteria: All participants: 1. Currently predominantly experiencing manic episodes; 2. Comorbid schizophrenia, organic brain disease, or substance dependence; 3. Severe physical illnesses (such as liver or kidney dysfunction, tumors); 4. Pregnant or breastfeeding women. Additional exclusions for the case group: 1. Patients in longitudinal treatment studies who have not used medications outside the study protocol at enrollment; 2. Unable to comply with follow-up or assessment scales.

Design outcomes

Primary

MeasureTime frame
Severity of Manic/Mixed Symptoms;Treatment remission rate: HAMD-17 score decrease >=50% (week 8);Symptom fluctuation: YMRS score decrease>=50%;

Secondary

MeasureTime frame
Severity of Depressive Symptoms;Levels of Endocrine Blood Biomarkers;Levels of Inflammatory Blood Biomarkers;Levels of Metabolic Blood Biomarkers;Levels of Coagulation Function Blood Biomarkers;

Countries

China

Contacts

Public ContactShujia Hu

Huzhou Third Municipal Hospital

2356585425@qq.com+86 572 213 2672

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 19, 2026